Fisher Asset Management LLC Purchases 27,690 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fisher Asset Management LLC boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 876,599 shares of the company's stock after purchasing an additional 27,690 shares during the period. Fisher Asset Management LLC owned about 1.01% of IDEAYA Biosciences worth $22,529,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. State Street Corp grew its position in shares of IDEAYA Biosciences by 15.4% in the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after buying an additional 443,640 shares during the last quarter. Barclays PLC boosted its holdings in IDEAYA Biosciences by 188.8% in the third quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after acquiring an additional 118,438 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in IDEAYA Biosciences by 12.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company's stock valued at $21,830,000 after purchasing an additional 78,518 shares during the period. Verition Fund Management LLC bought a new position in IDEAYA Biosciences during the 3rd quarter worth approximately $246,000. Finally, General American Investors Co. Inc. bought a new position in IDEAYA Biosciences during the 3rd quarter worth approximately $2,851,000. 98.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on IDYA. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Stephens reissued an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Finally, Wedbush reaffirmed an "outperform" rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $53.58.

Remove Ads

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA traded down $0.61 during midday trading on Friday, hitting $18.46. 830,295 shares of the stock traded hands, compared to its average volume of 887,734. IDEAYA Biosciences, Inc. has a one year low of $18.20 and a one year high of $47.44. The business has a 50 day moving average price of $22.79 and a two-hundred day moving average price of $28.19. The company has a market cap of $1.62 billion, a PE ratio of -5.59 and a beta of 0.76.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. As a group, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.